German maker of ophthalmic surgical devices and microscopes used in cataract, refractive and neurosurgical procedures.
German maker of ophthalmic surgical devices and microscopes used in cataract, refractive and neurosurgical procedures.
Sells surgical systems, diagnostic devices and microscopes up front, then earns repeat income from consumables such as intraocular lenses, the artificial lenses fitted after cataract removal, and from service contracts. Carl Zeiss AG, owned by the Carl Zeiss Foundation, holds the majority of the shares.
In one line: A German Alcon/Bausch+Lomb for ophthalmic devices.
Moat: narrow (IP / patents, brand, customer qualification). Leading optical/precision engineering and surgeon relationships in ophthalmic devices, competing with larger device makers.
Headquarters: Jena, Germany · Founded: 1990 · Employees: 5,784
Size Carl Zeiss Meditec (AFX.DE) is a Germany Health Care company (Medical Specialties) with a market value of $3.17B, the 87th largest of 198 Germany companies the cockpit tracks. Shares closed at €32.26 on 18 Nov 2026.
Performance Over six months the shares gained 22.2%, against -0.4% for the median peer and -0.9% for the Germany market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue fell 0.1% over the last twelve months (peer median +7.2%); the operating margin is 8.3% (peer median 9.4%).
Valuation It trades at 24.4× forward earnings against a peer median of 25.7× (9th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.8 points below its cost of capital (9.5% WACC).
Next results Next results expected around 10 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €2.17B | €2.23B | €2.07B | €2.09B | €1.90B |
| Revenue growth | — | +8% | -1% | +10% | — |
| Gross profit | €1.11B | €1.18B | €1.09B | €1.21B | €1.13B |
| EBITDA | €325M | €383M | €364M | €437M | €477M |
| Net income | €94.9M | €141M | €179M | €290M | €294M |
| Free cash flow | €273M | €170M | €161M | €185M | €145M |
| Capital expenditure | €63.2M | €76.6M | €152M | €114M | €82.0M |
| Total debt | n/a | €607M | €629M | €276M | €219M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Carl Zeiss Meditec AFX.DE | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% |
| Alcon ALC.SW | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% |
| Bausch + Lomb BLCO.TO | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% |
| Hoya 7741.T | $49.0B | -16% | +13% | 32% | 27.7× | 14.1% |
| RxSight RXST | n/a | -19% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AFX.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.4% | -3.4% | 10th lowest of 21 |
| 6-month return | +22.2% | -0.4% | 8th highest of 21 |
| Distance from 52-week high | -30.7% | -27.7% | 10th lowest of 21 |
| Revenue growth (TTM) | -0.1% | +7.2% | 5th lowest of 20 |
| Operating margin | 8.3% | 9.4% | 10th highest of 19 |
| Forward P/E | 24.4× | 25.7× | 9th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 12.5% | 11.3% | 9th least demanding of 17 |
| Growth delivered (Del g) | +10.8% | +8.0% | 6th highest of 17 |
| Hurdle (Req g minus delivered) | +1.7 pp | +1.2 pp | 8th most demanding of 17 |
| ROIC minus cost of capital | -4.8 pp | -1.1 pp | 7th lowest of 18 |
| EV / EBITDA | 10.8× | 24.0× | 4th cheapest of 11 |
| Net debt / EBITDA | 1.8× | 0.2× | 4th most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Celcuity CELC | United States | $2.73B | -60% | n/a | n/a | n/a | n/a | n/a |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $2.65B | -30% | +5% | 17% | 12.3× | -1.2% | +8.0% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |